The Indy Autonomous Challenge Presented by Bridgestone Returns to Goodwood Festival of Speed in July 2024
11.6.2024 17:00:00 EEST | Business Wire | Press release
Returning to showcase the World’s Fastest Autonomous Racecar, the Indy Autonomous Challenge (IAC), presented by Bridgestone, will take on the hillclimb at the Goodwood Festival of Speed presented by Mastercard from July 11th to July 14th, 2024. This year, the IAC’s AV-24 fully autonomous racecar will be piloted by software from the PoliMOVE-MSU team, with support from the UNIMORE Racing team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611138772/en/
The world's fastest autonomous racecar with an AI pilot coded by students from PoliMOVE-MSU team races on Goodwood Hill. Credit Indy Autonomous Challenge. (Photo: Business Wire)
The IAC has developed the AV-24, a fully autonomous racecar utilizing a Dallara chassis used in the Indy NXT series, and outfitted with a state-of-the-art robotics platform developed with leading autonomous hardware and software providers. To date, the IAC has organized autonomous racing competitions gathering 10 teams comprised of 18 universities at prestigious venues such as the Indianapolis Motor Speedway, Las Vegas Motor Speedway, Texas Motor Speedway, and Monza F1 Circuit—affectionately known as the Temple of Speed. The 2024 Festival of Speed marks the Indy Autonomous Challenge’s competitive debut in the UK, promising to test the technology in new and challenging ways.
Since its inception in 2021, the Indy Autonomous Challenge and its university teams have set several world records for high-speed ground-based autonomy:
- Autonomous land speed record of 192.2 mph
- Highest on-track speed of 180 mph
- Fastest head-to-head overtake on-track at 177 mph
- Most miles of autonomous racing accumulated: 9,000 miles.
Last year the Indy Autonomous Challenge was introduced to Goodwood in 2023 as part of Future Lab presented by Randox, illustrating the IAC’s significant role in advancing automotive driving technology through global events. Additionally, the Technical University of Munich used their autonomous racecar to conduct a low-speed scan of the Goodwood hill, crafting a digital twin of the course that will help enable this year’s fully autonomous hillclimb.
Paul Mitchell, Chairman and President of the Indy Autonomous Challenge, expressed enthusiasm about the upcoming event, stating, “We are eager to undertake the unique challenges presented by the Goodwood Hillclimb. Unlike the familiar ovals and F1 road courses, Goodwood’s Hillclimb will challenge the precision of sensor perception, GPS localization, vehicle dynamics, and path planning in new ways, providing a historical backdrop to showcase the future of high-speed autonomous mobility and the innovative university teams behind it.”
The event, part of Goodwood’s FOS TECH program, will highlight the latest in automotive technology and alternative fuels, integrating the Future Lab and STEM programs targeted at young people eager to participate in future robotics. IAC university teams’ capabilities will be showcased as they attempt an autonomous world record on the Goodwood hill. Autonomous racing will not only entertain but also offer insights and learnings towards the future of mobility, demonstrating how AI drivers will revolutionize vehicle safety and efficiency on public roads and within supply chains.
The Duke of Richmond, founder of the Festival of Speed, commented on the festival’s role in showcasing technological innovation: “This year, our new FOS TECH ethos will bring together our future technology and mobility content. Whether exploring Future Lab presented by Randox, Electric Avenue, or enjoying content on the Hill, visitors to the Festival of Speed can experience the work of groundbreaking innovators and their vision for tomorrow’s world.”
Sara Correa, Chief Marketing Officer for Bridgestone in the Americas, Europe, Middle East and Africa (EMEA) added, “What really matters is working together to collaboratively develop and advance the future of mobility. Bridgestone is proud to partner with the IAC and its young engineers to test and improve autonomous technologies through opportunities like the Goodwood Hillclimb. Motorsports are the ultimate challenge, and the learnings we gather here can be applied to the sustainable solutions we develop for society and our customers.”
Participating teams: PoliMOVE-MSU - Comprised of members from Politecnico di Milano (Italy), Michigan State University (Michigan), with the support of UNIMORE Racing - University of Modena and Reggio Emilia (Italy)
The IAC’s appearance at Goodwood Festival of Speed will be the first time that an exhibitor has graduated from Future Lab to the Hillclimb. This year’s event will also feature engaging educational sessions, where attendees can explore future technologies such as autonomous vehicles, drones, robots, augmented and virtual reality, generative AI, sensor fusion, and the Internet of Things. These topics will be the focus of a Q&A session in collaboration with Durham University's solar-powered electric car team, which has also worked with Bridgestone to advance sustainable mobility.
Earlier in June, the IAC conducted a series of training sessions on the Goodwood Hillclimb, performing fully autonomous runs of the hill, reaching speeds greater than 177 kph (110mph). Video and photo footage of the training sessions and racecar livery renders dedicated to media use can be found here.
About the IAC: The Indy Autonomous Challenge (IAC) is a non-profit corporation based in Indianapolis, Indiana (USA) that organizes racing competitions among 10 university-affiliated teams representing 18 universities from around the world. Teams program AI drivers to pilot fully autonomous racecars and compete in a series of history-making events at iconic tracks. Based in Indiana, the IAC is working to establish a hub for performance automation in the state and is harnessing the power of innovative competitions to attract the best and the brightest minds from around the globe to further state-of-the-art technology in the safety and performance of autonomous vehicles. The IAC started as a $1 million prize competition with 31 university teams signing up to compete more than three years ago, representing top engineering and technology programs from 15 U.S. states and 11 countries. Follow the IAC @IndyAChallenge on LinkedIn, Twitter, Instagram, Facebook, and YouTube.
About Bridgestone: Bridgestone is a global leader in tires and rubber building on its expertise to provide solutions for safe and sustainable mobility. Headquartered in Tokyo, the company employs approximately 130,000 people globally and conducts business in more than 150 countries and territories worldwide. Bridgestone offers a diverse product portfolio of premium tires and advanced solutions backed by innovative technologies, improving the way people around the world move, live, work and play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611138772/en/
Contacts
Marc Ferlet
marc.ferlet@indyautonomouschallenge.com
USA: +1 317 662 5070
FR: +33 6 79 16 96 26
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom